1-4 of 4
Anders E.A. Dahm, MD
Close
Sort by
Journal Articles

An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Peter AW te Boekhorst, MD PhD, Alexandre Theocharides, MD, Heinz Gisslinger, MD, Timothy Devos, MD, Eric Lippert, MD PhD, Damianos Sotiropoulos, MD, Miklos Egyed, MD PhD, Valerio De Stefano, MD, Vincenzo Accurso, MD, Alessandra Iurlo, MD PhD, Anders E.A. Dahm, MD PhD, Regina Garcia-Delgado, MD, Nathan Cantoni, MD, Mike Zuurman, PhD, Michael Zaiac, MD, Erik Houtsma, MSc, Amir Iqbal, PhD, Paola Di Matteo, MD PhD, Alberto Alvarez-Larrán, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–10.
https://doi.org/10.1182/blood-2020-134210
Published: 2020
Journal Articles

Production of Tissue Factor Pathway Inhibitor in Endothelial Cell Cultures Is Reduced by Estrogens, Selective Estrogen Receptor Modifiers, and a Selective Estrogen Receptor Downregulator.

Anders E.A. Dahm, MD, Nina Iversen, PhD, Baard Birkenes, Per Morten Sandset, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 3961.
https://doi.org/10.1182/blood.V106.11.3961.3961
Published: 2005
Journal Articles

Biological Relevance of a New TFPI Anticoagulant Activity Assay of Full-Length TFPI.

Anders E.A. Dahm, MD, Trine O. Andersen, Frits Rosendaal, MD, PhD, Per Morten Sandset, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 2982.
https://doi.org/10.1182/blood.V104.11.2982.2982
Published: 2004
Journal Articles

A Novel Assay for Tissue Factor Pathway Inhibitor (TFPI) Anticoagulant Activity in Plasma.

Anders E.A. Dahm, MD, Trine O. Andersen, Frits Rosendaal, MD, PhD, Per Morten Sandset, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 3987.
https://doi.org/10.1182/blood.V104.11.3987.3987
Published: 2004